<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04212715</url>
  </required_header>
  <id_info>
    <org_study_id>E-19-4346</org_study_id>
    <nct_id>NCT04212715</nct_id>
  </id_info>
  <brief_title>Prostate SABR With Intra-Prostatic SABR Boost</brief_title>
  <official_title>Prostate SABR With Intra-Prostatic SABR Boost: A Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King Saud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>King Saud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stereotactic Ablative Radiation (SABR/SBRT) will be prescribed to a dose of 35 Gy in 5
      fractions, once weekly to prostate with a simultaneous intra-prostatic boost to the MR
      detected nodule up to 50Gy. The pelvic lymph nodes and seminal vesicles will also receive 25
      Gy in 5 weekly fractions.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 26, 2019</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute Toxicity</measure>
    <time_frame>3 month after accrual is completed</time_frame>
    <description>To document the rate of acute urinary and bowel toxicity using the Common Terminology Criteria for Adverse Events (CTCAE) criteria</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Experimental arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SABR 35Gy/5 to prostate, up to 50Gy/5 to MR nodule, and 25Gy/5 to pelvic nodes and SVs</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Pelvic SABR with intra-prostatic SABR</intervention_name>
    <description>SABR 25Gy / 5 fractions to pelvis; 35Gy / 5 fractions to prostate; up to 50Gy / 5 fractions to MR nodule</description>
    <arm_group_label>Experimental arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed prostate adenocarcinoma

          -  High-risk prostate cancer, defined as at least one of: T3, Gleason 8-10, OR PSA &gt; 20
             ng/mL

          -  Willing to give informed consent to participate in this clinical trial

        Exclusion Criteria:

          -  Prior pelvic radiotherapy

          -  Contraindication to radical prostate radiotherapy e.g. connective tissue disease or
             inflammatory bowel disease

          -  Contraindication to prostate MRI

          -  No evidence of castrate resistance (defined as PSA &lt; 3 ng/ml while testosterone is &lt;
             0.7nmol/l. Patients could have been on combined androgen blockade but are excluded if
             this was started due to PSA progression.

          -  Definitive extrapelvic nodal or distant metastatic disease on staging investigations.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yasir Alayed, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>King Saud University Medical City</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yasir Alayed, MD</last_name>
    <phone>+966114671546</phone>
    <email>yalayed@ksu.edu.sa</email>
  </overall_contact>
  <location>
    <facility>
      <name>King Saud University Medical City</name>
      <address>
        <city>Riyadh</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yasir Alayed, MD</last_name>
      <phone>+966114671546</phone>
      <email>yalayed@ksu.edu.sa</email>
    </contact>
    <investigator>
      <last_name>Yasir Alayed, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Saudi Arabia</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 26, 2019</study_first_submitted>
  <study_first_submitted_qc>December 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 27, 2019</study_first_posted>
  <last_update_submitted>December 27, 2019</last_update_submitted>
  <last_update_submitted_qc>December 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>King Saud University</investigator_affiliation>
    <investigator_full_name>Dr. Yasir Alayed</investigator_full_name>
    <investigator_title>Consultant and Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

